Literature DB >> 16545650

Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease.

Harm H H Feringa1, Virginie H van Waning, Jeroen J Bax, Abdou Elhendy, Eric Boersma, Olaf Schouten, Wael Galal, Radosav V Vidakovic, Marco J Tangelder, Don Poldermans.   

Abstract

OBJECTIVES: We sought to investigate the effect of cardiac medication on long-term mortality in patients with peripheral arterial disease (PAD).
BACKGROUND: Peripheral arterial disease is associated with increased cardiovascular morbidity and mortality. Treatment guidelines recommend aggressive management of risk factors and lifestyle modifications. However, the potential benefit of cardiac medication in patients with PAD remains ill defined.
METHODS: In this prospective observational cohort study, 2,420 consecutive patients (age, 64 +/- 11 years, 72% men) with PAD (ankle-brachial index < or =0.90) were screened for clinical risk factors and cardiac medication. Follow-up end point was death from any cause. Propensity scores for statins, beta-blockers, aspirin, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, diuretics, nitrates, coumarins, and digoxin were calculated. Cox regression models were used to analyze the relation between cardiac medication and long-term mortality.
RESULTS: Medical history included diabetes mellitus in 436 patients (18%), hypercholesterolemia in 581 (24%), smoking in 837 (35%), hypertension in 1,162 (48%), coronary artery disease in 1,065 (44%), and a history of heart failure in 214 (9%). Mean ankle-brachial index was 0.58 (+/-0.18). During a median follow-up of eight years, 1,067 patients (44%) died. After adjustment for risk factors and propensity scores, statins (hazard ratio [HR] 0.46, 95% confidence interval [CI] 0.36 to 0.58), beta-blockers (HR 0.68, 95% CI 0.58 to 0.80), aspirins (HR 0.72, 95% CI 0.61 to 0.84), and ACE inhibitors (HR 0.80, 95% CI 0.69 to 0.94) were significantly associated with a reduced risk of long-term mortality.
CONCLUSIONS: On the basis of this observational longitudinal study, statins, beta-blockers, aspirins, and ACE inhibitors are associated with a reduction in long-term mortality in patients with PAD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545650     DOI: 10.1016/j.jacc.2005.09.074

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  27 in total

Review 1.  Beta-blocker contraindications: are there patients or situations where use is inappropriate?

Authors:  S D Naik; Ronald S Freudenberger
Journal:  Curr Heart Fail Rep       Date:  2007-06

Review 2.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh
Journal:  Circulation       Date:  2016-11-13       Impact factor: 29.690

Review 3.  Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?

Authors:  Michael J Osgood; David G Harrison; Kevin W Sexton; Kyle M Hocking; Igor V Voskresensky; Padmini Komalavilas; Joyce Cheung-Flynn; Raul J Guzman; Colleen M Brophy
Journal:  Ann Vasc Surg       Date:  2012-03-22       Impact factor: 1.466

Review 4.  Biomarkers of peripheral arterial disease.

Authors:  John P Cooke; Andrew M Wilson
Journal:  J Am Coll Cardiol       Date:  2010-05-11       Impact factor: 24.094

5.  Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia.

Authors:  Gregory G Westin; Ehrin J Armstrong; Heejung Bang; Khung-Keong Yeo; David Anderson; David L Dawson; William C Pevec; Ezra A Amsterdam; John R Laird
Journal:  J Am Coll Cardiol       Date:  2013-12-04       Impact factor: 24.094

Review 6.  Antithrombotic treatment for peripheral arterial disease.

Authors:  Daniel G Hackam; John W Eikelboom
Journal:  Heart       Date:  2006-10-11       Impact factor: 5.994

7.  Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction.

Authors:  Sumeet Subherwal; Deepak L Bhatt; Shuang Li; Tracy Y Wang; Laine Thomas; Karen P Alexander; Manesh R Patel; E Magnus Ohman; W Brian Gibler; Eric D Peterson; Matthew T Roe
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-06-19

Review 8.  Medical management for chronic atherosclerotic peripheral arterial disease.

Authors:  Farzana Nawaz Ali; Teresa L Carman
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

9.  Long-term mortality benefit of renin-angiotensin system inhibitors in patients with chronic limb-threatening ischemia undergoing vascular intervention.

Authors:  Thomas C F Bodewes; Jeremy D Darling; Thomas F X O'Donnell; Sarah E Deery; Katie E Shean; Murray A Mittleman; Frans L Moll; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2017-11-02       Impact factor: 4.268

Review 10.  Peripheral artery disease: potential role of ACE-inhibitor therapy.

Authors:  Giuseppe Coppola; Giuseppe Romano; Egle Corrado; Rosa Maria Grisanti; Salvatore Novo
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.